Head and neck squamous cell carcinoma (H&N SCC) incorporate tumours of varying areas of the upper aerodigestive tract,including the larynx,hypopharynx,nasopharynx,and oropharynx. H&N cancer is increasingly common in the UK,with rates increasing by 34% since the early 1990s. The rising prevalence of H&N cancer has been attributed to a rising rate in women,and the prevalence of the Human papilloma virus (HPV) in oropharyngeal cancer,which can account for up to 70% of cases. The survival in H&N cancer is highly variable,ranging from over ...

GO TO STUDY

Primary biliary cholangitis (PBC) is a rare liver disease. A number of treatments exist, which slow the rate that liver disease gets worse. However, at the moment, doctors have to wait for one treatment to fail before adding in a second. As a result, many people with PBC develop symptoms and some go on to need a liver transplant. The aim of the OPERA trial is to see if people who are newly/recently diagnosed with PBC have a better outcome if ...

GO TO STUDY

GT005, a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I, is currently being developed as a potential gene therapy for GA secondary to AMD. Current regulatory guidelines [EMA 2009; EMA 2018; FDA 2020] recommend that participants enrolled in gene therapy clinical trials with viral vectors that are non-replicating, non-integrating, and have no known potential for latency and re-activation should be followed for approximately 5 years post-treatment. The aim of this study (GT-ORACLE) is to evaluate ...

GO TO STUDY

Surgery remains the best option for the cure of patients with lung cancer. Around 7000 people in the UK undergo lung surgery each year, but up to 45% of patients developed post-operative complications leading to readmission to hospital and potentially poorer quality of life. National and international cancer, surgery and nutrition guidelines recommend a combination of exercise and nutritional support before and after surgery to help reduce post-operative complications. However it is not clear what is the best way to ...

GO TO STUDY

Breast cancer is the most common cancer worldwide and a leading cause of cancer-related death. Despite improvements in survival rates, a significant number of patients eventually develop distant metastasis after initial treatment. Metastatic breast cancer is difficult to diagnose and current tests including CT, MRIs, and PET scans are expensive and have low throughput. Biomarkers for metastatic cancer require specialised laboratory equipment, yet, their clinical utility is limited. This study aims to investigate the use of a point-of-care test LIT ...

GO TO STUDY

Although patients with COPD at high risk of exacerbations are prescribed azithromycin to reduce their risk of exacerbations, we do not know what happens if azithromycin is discontinued when patients are stable, or whether certain subgroups of patients with COPD gain benefit from azithromycin prevention treatment whereas others may not. This is a double-blind, adaptive design pragmatic randomised controlled trial to assess the benefits and risks of azithromycin complete discontinuation versus continued use in COPD patients. We aim to identify subgroups ...

GO TO STUDY

mRNA-4359 alone or in combination with pembrolizumab dependent on which arm the participant is assigned. mRNA-4359 dosing: mRNA-4359 will be given at the study site by injection into shoulder or thigh muscle (intramuscular [IM] injection) once every 3 weeks (Day 1 of every cycle). Up to 9 doses of mRNA-4359 will be given in this study, over an approximately 6-month period. Pembrolizumab dosing: If taking pembrolizumab in combination with mRNA-4539, pembrolizumab will be given at the study site by infusion into ...

GO TO STUDY

The primary objective is to determine whether there is a cyclical component to hypercortisolaemia in all patients diagnosed with endogenous Cushing’s syndrome. The secondary objective is to study post-operative CS patients who have features of CS recurrence and also to study patients with strong clinical suspicion for CS but no test is confirming the diagnosis. Study question in this group: how long should patients be monitored before it can be concluded that the patient does not have CS.

GO TO STUDY

The liver plays a key role in producing the proteins involved in blood clotting (haemostasis), both proteins promoting clotting (pro-coagulants) and those preventing clotting (anti-coagulants). It also has a role in removing these proteins from the circulation. Patients with liver disease have complex changes in haemostasis, which is overall ‘rebalanced’. When patients with liver disease are sick, and admitted to hospital, this rebalanced haemostasis is thought to be more unstable. These patients are at high risk of both bleeding and ...

GO TO STUDY

This is a single stage,single arm phase II,open,label,multi centre trial of patients with HER2 positive GOA who are ctDNA positive following neoadjuvant chemotherapy and surgery. HER2 positive will be defined as IHC3+ or IHC2+/ISH+ positive on diagnostic biopsy or resection specimen. ctDNA result will be determined using the Natera Signatera assay. All patients will be treated with trastuzumab deruxtecan at a dose of 6.4 mg/kg intravenously every 21 days for 6 months. If required patients may dose reduce to 5.4 ...

GO TO STUDY